OIS@AAO 2016 Videos

Dosing of the suprachoroidal space with Zuprata, Clearside Biomedical’s proprietary triamcinolone formulation, can provide high bioavailability of drug to the retina and choroid while avoiding…

The OIS Index, a composite of ophthalmic growth stocks, was introduced at OIS@AAO. The purpose of the OIS Index is to provide a tool for…

Since a congressional mandate required the National Institutes of Health to set aside 3% of its total funding for small business grants, the National Eye…

CHICAGO—Some of the world’s largest ophthalmic companies were represented here during OIS@AAO to discuss what it takes to build a successful ophthalmic franchise. Panel moderator…

CHICAGO—This year’s OIS Industry Tribute celebrated one of the best-known names in ophthalmology: Allergan. The Dublin-based company is one that “we rely on for innovation…

The methodology private and government payers use to measure quality outcomes in health care is changing, David W. Parke II, MD, CEO of the American…

Ophthalmology remains one of the likeliest targets for technology companies looking to make an impact – and to build a business – within health care.…

Ashley McEvoy, company group chairman, Johnson & Johnson Vision, shares why ophthalmology is attractive to J&J and other players. In discussing Abbott Medical Optics, McEvoy…

CHICAGO—A combination of phenylephrine 1% and ketorolac 0.3% injection is “the first and only FDA-approved intraocular product to prevent miosis and to reduce postop ocular…

Quinton Oswald, CEO of Notal Vision, introduced the company’s ForeseeHome diagnostic tool for wet age-related macular degeneration (AMD). The company is looking to move diagnosis…

Opthea, a public company listed on the Australian Stock Exchange, is developing OPT-302, a novel therapy for wet age-related macular degeneration (AMD). The company’s lead…